Eledon Pharmaceuticals, Inc. financial data

Symbol
ELDN on Nasdaq
Location
19800 Macarthur Blvd., Suite 250, Irvine, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 982 % -4.03%
Debt-to-equity 88.7 %
Return On Equity -154 % -389%
Return On Assets -52 % -143%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 59.9M shares +0.32%
Common Stock, Shares, Outstanding 59.9M shares +45.4%
Entity Public Float 64.9M USD +153%
Common Stock, Value, Issued 60K USD +46.3%
Weighted Average Number of Shares Outstanding, Basic 77.2M shares +48.5%
Weighted Average Number of Shares Outstanding, Diluted 77.2M shares +39.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 66.7M USD +62.3%
General and Administrative Expense 19.8M USD +30.7%
Operating Income (Loss) -19.1M USD +7.02%
Net Income (Loss) Attributable to Parent -79.8M USD -268%
Earnings Per Share, Basic 0 USD/shares +54.5%
Earnings Per Share, Diluted 0 USD/shares +25%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.67M USD -45.7%
Cash, Cash Equivalents, and Short-term Investments 93.4M USD +19.4%
Other Assets, Current 14K USD -96.8%
Assets, Current 96.3M USD +18.1%
Operating Lease, Right-of-Use Asset 694K USD +47.3%
Goodwill 0 USD
Other Assets, Noncurrent 476K USD +127%
Assets 130M USD +13.3%
Accounts Payable, Current 4.63M USD -21%
Liabilities, Current 14.3M USD +14.5%
Deferred Income Tax Liabilities, Net 2.18M USD +24.6%
Operating Lease, Liability, Noncurrent 376K USD +19.4%
Liabilities 38.8M USD +0.74%
Accumulated Other Comprehensive Income (Loss), Net of Tax 9K USD -91.2%
Retained Earnings (Accumulated Deficit) -391M USD -25.7%
Stockholders' Equity Attributable to Parent 35.4M USD +73.6%
Liabilities and Equity 130M USD +13.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -16.1M USD -83.7%
Net Cash Provided by (Used in) Financing Activities 115K USD
Net Cash Provided by (Used in) Investing Activities 3.89M USD -60.2%
Common Stock, Shares Authorized 300M shares +50%
Common Stock, Shares, Issued 59.9M shares +45.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -12.1M USD -1256%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.67M USD -45.7%
Deferred Tax Assets, Valuation Allowance 46.4M USD +50.5%
Deferred Tax Assets, Gross 52M USD +41.3%
Operating Lease, Liability 722K USD +44.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -17.4M USD -123%
Lessee, Operating Lease, Liability, to be Paid 795K USD +39.2%
Operating Lease, Liability, Current 346K USD +86%
Lessee, Operating Lease, Liability, to be Paid, Year Two 293K USD +48.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 403K USD +111%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 73K USD +4.29%
Lessee, Operating Lease, Liability, to be Paid, Year Three 293K USD
Deferred Tax Assets, Operating Loss Carryforwards 22.7M USD +25.7%
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 6.23M USD +71.4%
Operating Lease, Payments 97K USD -4.9%
Share-based Payment Arrangement, Expense 14.6M USD +76.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%